Juno Picks Up A2a Receptor Via Redox Acquisition
Juno Therapeutics Inc. has followed in the footsteps of some of its big pharma rivals, Novartis and AstraZeneca, by acquiring RedoxTherapies, Inc. for its small molecule adenosine A2a (A2a) receptor antagonist vipadenant.
You may also be interested in...
Juno Therapeutics President and CEO Hans Bishop spoke with Scrip about the company's CAR-T strategy, its short-lived clinical hold and Novartis's recent cell therapy business shift.
Allergan backs out of deal with Adamis for an EpiPen competitor just two months after signing the licensing deal, but before an up-front payment due date kicks in. AbCellera to team with MassBiologics to discover antibodies against drug-resistant Klebsiella infections.
Novartis has revealed a series of deals which widen its net in immune-oncology, and hopefully compensate for falling behind some of its competitors in this key development area.